Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2023-02-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：审计委员会会议日期
Regulatory Filings Classification · 95% confidence The document is a short announcement from BeiGene, Ltd. regarding the date of the Audit Committee meeting to review and approve the audited financial results for the year ended December 31, 2022. It states that the audited results prepared under US GAAP and SEC rules will be reviewed on February 27, 2023, and that the audited results prepared under Hong Kong Listing Rules will be published by March 31, 2023. The document does not contain the actual audited financial statements or detailed audit report, but rather announces the timing and scope of the audit committee meeting and forthcoming results. The document length is only 865 characters, which is very short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE and the nature of the content, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about audit committee meeting and upcoming audited results, not the audit report itself or the annual report.
2023-02-14 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipt issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirmations related to share issuance and compliance with listing rules. The document is structured as a regulatory monthly report on share capital and share issuance activities, not a full financial report or earnings release. It is not an announcement of voting results, board changes, or legal proceedings. The content aligns with disclosures about share capital changes and issuance, which fits the category of Share Issue/Capital Change filings. The document length is 4695 characters, which is substantive and contains detailed data on share movements, not just an announcement or certification. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2023-02-06 Chinese
美股公告：临时报告8-K表格
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC), which is a current report used to announce major events that shareholders should know about. The text references the 1934 Securities Exchange Act and specifies that it is a "临时报告" (interim or current report) under Sections 13 or 15(d). The content describes a significant amendment to a previously disclosed agreement regarding share issuance and board appointment rights, which is typical of an 8-K filing. The document length is 2163 characters, which is relatively short and consistent with an 8-K report. It is not an annual or quarterly report, nor a transcript or presentation. Therefore, the correct classification is Regulatory Filings (RNS), as 8-K filings are general regulatory announcements that do not fit into other specific categories like Annual Report or Earnings Release.
2023-02-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) that require disclosure of share capital changes. The document includes detailed tables of share issuance, dates, prices, and percentages, as well as confirmations that the share issuances were authorized and complied with regulatory requirements. The document length is about 3,081 characters, which is relatively short but contains substantive data on share capital changes rather than just an announcement of a report. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2023-02-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It details share issuance under a share award plan, including share counts, issue prices, and percentage changes. The document includes confirmations that the share issuance was authorized and complies with listing requirements. The document length is 2876 characters, which is relatively short and focused on share capital changes rather than a full financial report or earnings release. This matches the definition of a Share Issue/Capital Change announcement (SHA). It is not an Annual Report, Earnings Release, or Regulatory Filing, but a specific disclosure of share capital changes as per listing rules.
2023-01-30 Chinese
港股公告：授出购股权及受限制股份单位
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the grant of share options and restricted share units under the 2016 Option and Incentive Plan by BeiGene, Ltd. It includes specifics such as grant dates, number of shares, exercise prices, vesting schedules, and terms of the awards. The content focuses on equity compensation awards to employees and the related terms and conditions. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a regulatory certification or a report publication announcement. The document is a formal announcement related to share-based compensation, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Director's Dealing (DIRS) since it is about grants, not personal trades, nor is it a capital change announcement (SHA) because it does not announce new share issuance but rather option grants under an existing plan. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-01-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.